ReNewed Sensation: Improving Awareness, Diagnosis, and Treatment of Neurotrophic Keratitis (CME Monograph)
Activity Description and Purpose
Neurotrophic keratitis (NK) is characterized by disrupted tearing and progressive corneal damage that does not readily heal. Until very recently, a lack of approved treatments to reinnervate and heal eyes affected by NK served to further hamper efforts toward timely diagnosis. Now that an approved therapeutic agent is available, ophthalmologists are better armed to identify patients with early stages of NK and to better strategize individual treatment regimens before the disease progresses to the point of corneal perforation and subsequent loss of visual acuity. The desired results of this educational activity are for ophthalmologists to have a better understanding of the pathophysiology of NK, newly developed disease stage classification, and current best practices for screening, diagnosis, and treatment.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Describe the pathophysiology of neurotrophic keratitis
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
- Review evidence of corneal healing and reinnervation in patients treated with recombinant human nerve growth factor
- Identify treatment strategies for patients diagnosed with any stage of neurotrophic keratitis
Edward J. Holland, MD (Chair)
Professor of Clinical Ophthalmology
University of Cincinnati
Director, Cornea Services
Cincinnati Eye Institute
Preeya K. Gupta, MD
Associate Professor of Ophthalmology
Cornea & Refractive Surgery
Duke University Eye Center
Durham, North Carolina
Francis S. Mah, MD
Director, Cornea and External Diseases
Co-Director, Refractive Surgery
Scripps Clinic Torrey Pines
La Jolla, California
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Preeya K. Gupta, MD, is a consultant for Dompé US, Inc.
Edward J. Holland, MD, is a consultant for Aerie Pharmaceuticals, Inc, Akros Pharma Inc, Alcon, Aldeyra Therapeutics, Allegro Ophthalmics, LLC, Allergan, Azura Ophthalmics Ltd, BlephEx, BRIM Biotechnology, Inc, Claris Bio, CorneaGen, CorNeat Vision Ltd, Dompé US, Inc, Expert Opinion, EyePoint Pharmaceuticals, Glaukos Corporation, Hanall Biopharma, Invirsa Inc, Kala Pharmaceuticals, Mati Therapeutics, Inc, Merck KGgA, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Ocuphire Pharma, Omeros Corporation, Oyster Point Pharma, Inc, Precise Biosciences, Prometic Biotherapeutics, Inc, ReGenTree, LLC, ReTEAR, Inc, Senju Pharmaceutical Co, Ltd, Shire, Sight Sciences, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Vomaris Innovations, Inc, W. L. Gore and Associates, Inc, and Zeiss; and is on the speakers bureau for Alcon, Novartis Pharmaceuticals Corporation, Omeros Corporation, Senju Pharmaceutical Co, Ltd, and Shire.
Francis S. Mah, MD, is a consultant for Dompé US, Inc, and EyeVance; and is on the speakers bureau for Dompé US, Inc.
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dompé US, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC; Dompé US, Inc; EyeNet; or the American Academy of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 234
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation